Evidences showed that ATF4 inhibition promoted the ferroptosis process induced by sorafenib in HCC with increased lipid peroxidation, decreased GSH, and decreased cell viability, which could be suppressed by ferrostatin-1 as well as forced expression of SLC7A11, suggesting that ATF4 was involved in resistance to ferroptosis in HCC through the regulation of SLC7A11. Here, SLC7A11 is linked to hepatocellular carcinoma.